Breakthroughs in Treatments for Idiopathic Pulmonary Fibrosis

With the approval of two new drugs for the treatment of IPF, patients who otherwise would have only had lung transplantation as a treatment option now have a new way to improve their quality of life.

At the 2014 annual meeting of the American College of Chest Physicians in Austin, TX, the drug approvals were a topic of considerable discussion. Steven Nathan, MD, FCCP, discusses some of the advances made and what work remains to help patients with this complex, hard-to-treat condition.